|
Index | - | P/E | - | EPS (ttm) | -6.53 | Insider Own | 4.47% | Shs Outstand | 9.85M | Perf Week | -13.85% |
Market Cap | 502.07M | Forward P/E | - | EPS next Y | -1.27 | Insider Trans | 0.00% | Shs Float | - | Perf Month | -18.33% |
Income | -61.20M | PEG | - | EPS next Q | -0.55 | Inst Own | 36.90% | Short Float | - | Perf Quarter | -16.60% |
Sales | 23.20M | P/S | 21.64 | EPS this Y | 24.70% | Inst Trans | 112.82% | Short Ratio | 2.94 | Perf Half Y | -29.50% |
Book/sh | -2.25 | P/B | - | EPS next Y | 68.30% | ROA | -94.40% | Target Price | - | Perf Year | 196.12% |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | -448.70% | 52W Range | 1.18 - 14.88 | Perf YTD | -30.19% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | -101.20% | 52W High | -47.31% | Beta | - |
Dividend % | - | Quick Ratio | 6.60 | Sales past 5Y | - | Gross Margin | - | 52W Low | 564.41% | ATR | 0.62 |
Employees | 72 | Current Ratio | 6.60 | Sales Q/Q | -70.00% | Oper. Margin | - | RSI (14) | 26.62 | Volatility | 7.11% 6.76% |
Optionable | No | Debt/Eq | - | EPS Q/Q | -226.20% | Profit Margin | - | Rel Volume | 0.70 | Prev Close | 8.20 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 516.12K | Price | 7.84 |
Recom | 1.20 | SMA20 | -16.26% | SMA50 | -27.23% | SMA200 | -14.28% | Volume | 363,265 | Change | -4.39% |
![]() | ||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a A'bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. | ||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite